Intract Pharma
Intract Pharma is dedicated to transforming patient care by replacing injections with safer, more effective oral therapeutics. They develop innovative technologies for targeted drug delivery in the gastrointestinal tract, including their flagship technologies Soteria® and Phloral®. The company focuses on enabling oral biologics delivery, advancing scientific research, and forming strategic collaborations to bring novel therapies to market.
Industries
Nr. of Employees
small (1-50)
Intract Pharma
London, England, United Kingdom, Europe
Products
Colon-targeted dual-trigger coating technology
A coating approach combining pH-responsiveness and microbiota-triggered enzymatic degradation to provide reproducible and site-specific release in the colon.
Oral biologics tablet/capsule formulation platform with core absorption enhancer
Formulation platform for converting injectable biologics into oral solid-dosage forms that protect actives through the stomach/small intestine, release in the colon, and use core enhancers to reduce enzymatic degradation and increase mucosal uptake.
Dynamic dissolution testing platform with bicarbonate-based media and automated pH control
In vitro testing platform using physiological bicarbonate buffers and an automated pH-control system to simulate GI transit and generate IVIVC for modified-release products.
Colon-targeted dual-trigger coating technology
A coating approach combining pH-responsiveness and microbiota-triggered enzymatic degradation to provide reproducible and site-specific release in the colon.
Oral biologics tablet/capsule formulation platform with core absorption enhancer
Formulation platform for converting injectable biologics into oral solid-dosage forms that protect actives through the stomach/small intestine, release in the colon, and use core enhancers to reduce enzymatic degradation and increase mucosal uptake.
Dynamic dissolution testing platform with bicarbonate-based media and automated pH control
In vitro testing platform using physiological bicarbonate buffers and an automated pH-control system to simulate GI transit and generate IVIVC for modified-release products.
Services
Licensing and product development partnerships
License-out of drug-delivery platforms and collaborative development agreements to enable third parties to develop orally delivered therapeutics using the company's formulation technologies.
In vitro GI testing and formulation evaluation services
Laboratory services including dynamic dissolution testing, bicarbonate-buffered media assays, and GI stability/permeability profiling to assess formulation behaviour and support candidate selection.
Licensing and product development partnerships
License-out of drug-delivery platforms and collaborative development agreements to enable third parties to develop orally delivered therapeutics using the company's formulation technologies.
In vitro GI testing and formulation evaluation services
Laboratory services including dynamic dissolution testing, bicarbonate-buffered media assays, and GI stability/permeability profiling to assess formulation behaviour and support candidate selection.
Expertise Areas
- Oral biologics delivery
- Colonic drug targeting
- Formulation development for enteric and modified-release systems
- In vitro dissolution modelling and IVIVC
Key Technologies
- pH- and microbiota-triggered enteric coatings
- Dual-action formulation enhancers for enzymatic protection and uptake
- Bicarbonate-based dissolution media
- Automated pH-control dissolution systems